Another Low Blow For Raising HDL; Merck’s Tredaptive Fails Phase III Trial

With Tredaptive’s failure to meet the primary endpoint in the HPS2-THRIVE study, Merck announces it does not plan to seek regulatory approval of the niacin/laropiprant combination pill in the U.S.